Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin.

Roux C, Pelissier C, Listrat V, Kolta S, Simonetta C, Guignard M, Dougados M, Amor B

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA1 May 1995Cited by 18 (Europe PMC)

PMID7655179DOI10.1007/bf02106098PepBankPUB-07655179

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 100 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 100 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeEstradiol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517901
02HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, bone metabolism markers did not differ between salmon calcitonin 100 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, bone metabolism markers did not differ between salmon calcitonin 100 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBone metabolism markers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517902
03HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, bone loss did not differ between salmon calcitonin 100 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, bone loss did not differ between salmon calcitonin 100 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBone loss at all sites
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no difference in bone loss in the three groups, at all sites.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517903
04HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 200 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, estradiol did not differ between salmon calcitonin 200 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeEstradiol
Study
n: not reported in source
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
200 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517904
05HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, bone metabolism markers did not differ between salmon calcitonin 200 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, bone metabolism markers did not differ between salmon calcitonin 200 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBone metabolism markers
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517905
06HumanRandomized controlled trialEfficacy outcome
In endometriosis patients receiving triptoreline and calcium, bone loss did not differ between salmon calcitonin 200 IU daily and placebo.
In plain wordsIn endometriosis patients receiving triptoreline and calcium, bone loss did not differ between salmon calcitonin 200 IU daily and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBone loss at all sites
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 6 monthsAs given in this study (human).
Source sentences
Summary
There was no difference in bone loss in the three groups, at all sites.
1 context sentence(design, population, supporting numbers)
Summary · context
To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups-placebo, sCT 100 IU daily and sCT 200 IU daily-in a prospective double-masked study.
Report a problemFND-0765517906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.